Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NVO 
Novo Nordisk A/S (NVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NVO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 69.24% | Avg. Invested days 84 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 304.59B USD | Price to earnings Ratio 21.17 | 1Y Target Price 107.29 |
Price to earnings Ratio 21.17 | 1Y Target Price 107.29 | ||
Volume (30-day avg) 7440773 | Beta 0.17 | 52 Weeks Range 66.88 - 145.26 | Updated Date 04/1/2025 |
52 Weeks Range 66.88 - 145.26 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 2.33% | Basic EPS (TTM) 3.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 34.78% | Operating Margin (TTM) 49.69% |
Management Effectiveness
Return on Assets (TTM) 22.41% | Return on Equity (TTM) 80.78% |
Valuation
Trailing PE 21.17 | Forward PE 17.36 | Enterprise Value 315657133375 | Price to Sales(TTM) 1.05 |
Enterprise Value 315657133375 | Price to Sales(TTM) 1.05 | ||
Enterprise Value to Revenue 7.44 | Enterprise Value to EBITDA 15.74 | Shares Outstanding 3364179968 | Shares Floating 3184951970 |
Shares Outstanding 3364179968 | Shares Floating 3184951970 | ||
Percent Insiders - | Percent Institutions 10.27 |
Analyst Ratings
Rating 3.82 | Target Price 114.68 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 2 | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Novo Nordisk A/S
Company Overview
History and Background
Novo Nordisk A/S was founded in 1923 in Denmark. It evolved from the Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, initially focused on insulin production. Over time, it expanded into diabetes care, obesity treatment, and biopharmaceuticals.
Core Business Areas
- Diabetes Care: The largest segment, focused on insulin, GLP-1 receptor agonists, and oral antidiabetic drugs. It contributes the most to revenue.
- Obesity Care: Focused on treatments for obesity, including GLP-1 receptor agonists, experiencing rapid growth.
- Rare Disease: Developing and marketing treatments for rare bleeding disorders, growth disorders, and other rare diseases.
Leadership and Structure
Novo Nordisk is led by a President and CEO, supported by an executive management team. It has a two-tier board structure (management and supervisory boards) reflecting Danish corporate governance practices.
Top Products and Market Share
Key Offerings
- Ozempic (semaglutide): A GLP-1 receptor agonist for type 2 diabetes. Has a large market share in GLP-1 market. Competitors include Trulicity (LLY) and Mounjaro (LLY).
- Rybelsus (oral semaglutide): The first oral GLP-1 receptor agonist for type 2 diabetes. Market share growing rapidly. Competitors include other oral antidiabetic medications and GLP-1 injectables.
- Wegovy (semaglutide): A higher-dose semaglutide approved for chronic weight management. Leading GLP-1 obesity drug. Competitors include Saxenda and other weight loss drugs.
- NovoLog (insulin aspart): A rapid-acting insulin analog used to control blood sugar levels in people with diabetes. NovoLog and other insulins face competition from other insulin brands, as well as GLP-1 receptor agonists and other diabetes medications.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny. The diabetes and obesity markets are growing due to rising prevalence rates.
Positioning
Novo Nordisk is a leading player in the diabetes and obesity care markets, with a strong portfolio of innovative products. It has a competitive advantage in GLP-1 receptor agonists.
Total Addressable Market (TAM)
The global diabetes and obesity market is estimated to be worth hundreds of billions of dollars annually. Novo Nordisk is well-positioned to capture a significant share of this TAM through its innovative products.
Upturn SWOT Analysis
Strengths
- Strong market position in diabetes and obesity care
- Innovative product portfolio, especially GLP-1 agonists
- Global presence and distribution network
- Strong R&D capabilities
- High brand recognition
Weaknesses
- Reliance on a few key products
- Exposure to biosimilar competition for insulin products
- High R&D expenses
- Pricing pressures in the pharmaceutical industry
Opportunities
- Expanding into new therapeutic areas
- Developing new and improved treatments for diabetes and obesity
- Increasing market share in emerging markets
- Strategic acquisitions and partnerships
- Expanding indications for existing drugs.
Threats
- Increasing competition from other pharmaceutical companies
- Pricing pressures and reimbursement challenges
- Regulatory changes and increased scrutiny
- Patent expirations and biosimilar competition
- Adverse events or safety concerns related to products
Competitors and Market Share
Key Competitors
- LLY
- SNY
- MRK
- NVO
Competitive Landscape
Novo Nordisk holds a competitive edge in the GLP-1 market. Competitors like LLY are aggressively trying to catch up. SNY focuses on other areas of diabetes management. Other companies have a smaller presence in the space.
Major Acquisitions
Dicerna Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 3300
- Strategic Rationale: To strengthen Novo Nordisk's research and development capabilities in RNA interference (RNAi) therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Novo Nordisk has experienced strong growth in recent years, driven by demand for its diabetes and obesity treatments.
Future Projections: Analyst estimates vary but generally project continued growth for Novo Nordisk, driven by its innovative product portfolio.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, launching new products, and strategic acquisitions.
Summary
Novo Nordisk is a robust company with a leading position in diabetes and obesity care. Its innovative GLP-1 receptor agonists drive growth. However, it faces increasing competition and pricing pressures. Expanding manufacturing is also a current challenge for the company.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company filings (SEC.gov), Financial news websites (Yahoo Finance, Google Finance), Analyst reports, Novo Nordisk investor relations
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates may vary depending on the source. The AI-based rating is based on an automated analysis and should not be considered a definitive assessment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novo Nordisk A/S
Exchange NYSE | Headquaters - | ||
IPO Launch date 1982-01-04 | President, CEO & Member of Management Board Mr. Lars Fruergaard Jorgensen | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 76302 | Website https://www.novonordisk.com |
Full time employees 76302 | Website https://www.novonordisk.com | ||
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.